MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02989064|
Recruitment Status : Recruiting
First Posted : December 12, 2016
Last Update Posted : January 3, 2019
This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects at least 18 years of age using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Following the dose escalation phase, additional subjects will be enrolled at the target cell dose range to further characterize safety and the effects at this cell dose.
The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells. When the MAGE-A10ᶜ⁷⁹⁶T cells are available, subjects will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by T cell infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with urothelial, melanoma or head and neck cancer.
Subjects will be seen frequently by the Study Physician after receiving their T cells for the next 6 months. After that, subjects will be seen every 3, 6, or 12 months according to the Schedule of Procedures. All subjects completing or withdrawing from the interventional portion of the study will enter a long term follow-up phase for observation of delayed adverse events and overall survival for 15 years post-infusion.
|Condition or disease||Intervention/treatment||Phase|
|Urinary Bladder Cancer Head and Neck Cancer Melanoma||Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors|
|Study Start Date :||October 2016|
|Estimated Primary Completion Date :||November 2019|
|Estimated Study Completion Date :||May 2020|
|Experimental: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells||
Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
- Number of subjects with adverse events (AE), including serious adverse events (SAE). [ Time Frame: 3 years ]Determine if treatment with autologous genetically modified T cells, (MAGE A10ᶜ⁷⁹⁶T ) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation; and cardiac assessments, including ECG/troponin.
- Evaluation of the persistence of genetically modified T cells [ Time Frame: 3 years ]Evaluation of the persistence of the infused T cells in the periphery.
- Measurement of RCL in genetically modified T cells. [ Time Frame: 3 years ]Evaluation of RCL in Subject PBMCs using PCR-based assay.
- Assessment of dose limiting toxicities to determine optimally tolerated dose range [ Time Frame: 3 years ]Evaluation of dose limiting toxicities will be performed using the CTCAE Version 4.0
- Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR). [ Time Frame: 3 years ]Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1
- Interval between the date of first T cell infusion dose and first documented evidence of CR or PR. [ Time Frame: 3 years ]Evaluation of the efficacy of the treatment by assessment of time to first response.
- Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause. [ Time Frame: 3 years ]Evaluation of the efficacy of the treatment by assessment of duration of response.
- Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause. [ Time Frame: 3 years ]Evaluation of the efficacy of the treatment by assessment of duration of stable disease.
- Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause [ Time Frame: 3 years ]Evaluation of the efficacy of the treatment by assessment of progression-free survival.
- Interval between the date of first T cell infusion and date of death due to any cause. [ Time Frame: 3 years ]Evaluation of the efficacy of the treatment by assessment of overall survival.
- Number and % of subjects having any Long Term Follow Up Adverse Events (AEs) [ Time Frame: 15 years post last treatment (infusion) ]
- New occurrence of any malignancy
- New occurrence or exacerbation of a pre-existing neurologic disorder
- New occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder
- New occurrence of a hematologic disorder
- New occurrence of any opportunistic and/or serious infections
- New occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02989064
|Contact: David Hong, MD||713-563-1930|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Ryan Sullivan, MD 617-724-4000 firstname.lastname@example.org|
|Principal Investigator: Ryan Sullivan, MD|
|United States, Missouri|
|Washington University - School of Medicine||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Nic Perry 314-273-2831 email@example.com|
|Principal Investigator: Russell Pachynski, MD|
|United States, New York|
|Roswell Park Cancer Institute||Recruiting|
|Buffalo, New York, United States, 14263|
|Contact: Amy Whitworth 716-845-3089 Amy.Whitworth@roswellpark.org|
|Principal Investigator: Gurkamal Chatta, MD|
|United States, Pennsylvania|
|Fox Chase Cancer Center||Recruiting|
|Philadelphia, Pennsylvania, United States, 19111|
|Contact: Anthony Olszanski, MD, RPh Anthony.Olszanski@FCCC.edu|
|Principal Investigator: Anthony Olszanski, MD, RPh|
|United States, Tennessee|
|Tennessee Oncology - Sarah Cannon Research Institute||Recruiting|
|Nashville, Tennessee, United States, 37203|
|Contact 615-339-4214 firstname.lastname@example.org|
|Principal Investigator: Melissa Johnson, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Danxia Ke 713-792-4384 email@example.com|
|Contact: Ly M Nguyen|
|Principal Investigator: David S Hong, MD|
|Princess Margaret Cancer Centre||Recruiting|
|Toronto, Ontario, Canada, M5G1X6|
|Contact: Marcus Butler, MD 416-946-4501 TIP@uhn.ca|
|Contact: Anna Spreafico|
|Principal Investigator: Marcus Butler, MD|
|Principal Investigator:||David Hong, MD||M.D. Anderson Cancer Center|